Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.

@article{Mathijssen2004PredictionOI,
  title={Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.},
  author={Ron H. J. Mathijssen and Floris A. de Jong and Ron H. N. van Schaik and Erin R Lepper and Lena E. Friberg and Trinet Rietveld and Peter J de Bruijn and Wilfried J. Graveland and William D. Figg and Jaap Verweij and Alex Sparreboom},
  journal={Journal of the National Cancer Institute},
  year={2004},
  volume={96 21},
  pages={1585-92}
}
BACKGROUND Irinotecan is a topoisomerase I inhibitor that has been approved for use as a first- and second-line treatment for colorectal cancer. The response to irinotecan is variable, possibly because of interindividual variation in the expression of the enzymes that metabolize irinotecan, including cytochrome P450 3A4 (CYP3A4) and uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1). We prospectively explored the relationships between CYP3A phenotype, as assessed by erythromycin… CONTINUE READING